| Literature DB >> 11604319 |
Abstract
Transgenic plants are showing considerable potential for the economic production of proteins, with a few already being marketed. Recent clinical trials of pharmaceuticals produced from transgenic plants are encouraging, with plant glycans showing reassuringly poor immunogenicity. Our increasing understanding of protein targeting and accumulation should further improve the potential of this new technology.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11604319 DOI: 10.1016/s0958-1669(00)00244-5
Source DB: PubMed Journal: Curr Opin Biotechnol ISSN: 0958-1669 Impact factor: 9.740